Page 68 - Merck Sharp News Today

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the...

The increment in Checkpoint Inhibitor Refractory Cancer market size is due to high potency against cancer cells, increase in R&D activity, rise in the cases of types of cancers, where checkpoint

- ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types - - Company to Host Investor Webcast on June

PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into EuropePromising preliminary clinical results validate expansion of study initially into the United Kingdom - read this article along with other careers information, tips and advice on BioSpace

The increase in the LAG 3 Next Generation Immunotherapy market size is a direct consequence of the expected entry of premium LAG-3 drugs and their readily...

Press release content from Business Wire. The AP news staff was not involved in its creation.

As reported previously, courts in both Ireland (in February 2022, concerning Inegy®) and Finland (in November 2021, concerning Janumet®) have recently identified an apparent discrepancy in CJEU case law with...

Keytruda is for women with incurable secondary triple negative breast cancer and its aim is to slow disease progression.

This new treatment will be able to be used alongside chemotherapy

British women with incurable secondary triple negative breast cancer will get a new life-extending treatment after the NHSs drug watchdog reversed a previous rejection.